Wednesday, 26 August 2026European Markets

NEW SOURCES ENERGY Stock Went Down By Over 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NEW SOURCES ENERGY (AEX-Index: NSE.AS) fell by a staggering 33.33% in 21 sessions from €0.06 to €0.04 at 05:09 EST on Thursday, following the last session's downward trend. AEX-Index is falling 0.38% to €760.22, following the last session's downward trend.

About NEW SOURCES ENERGY

New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.

Volatility

NEW SOURCES ENERGY's last week, last month's, and last quarter's current intraday variation average was a negative 10.74%, a negative 2.85%, and a positive 5.11%.

NEW SOURCES ENERGY's highest amplitude of average volatility was 12.29% (last week), 7.44% (last month), and 5.11% (last quarter).

Volume

Today's last reported volume for NEW SOURCES ENERGY is 12870 which is 350.17% above its average volume of 18832.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEW SOURCES ENERGY's stock is considered to be overbought (>=80).

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com